Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

IDYA

IDEAYA Biosciences (IDYA)

IDEAYA Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IDYA
DateTimeSourceHeadlineSymbolCompany
01/12/202511:00AMPR Newswire (US)IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate GuidanceNASDAQ:IDYAIDEAYA Biosciences Inc
12/30/20245:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
12/29/20245:00AMPR Newswire (US)IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
12/27/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
12/20/20243:53PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
12/17/20245:00AMPR Newswire (US)IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal MelanomaNASDAQ:IDYAIDEAYA Biosciences Inc
12/16/20245:00AMPR Newswire (US)IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung CancersNASDAQ:IDYAIDEAYA Biosciences Inc
12/11/20245:00AMPR Newswire (US)IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024NASDAQ:IDYAIDEAYA Biosciences Inc
12/10/20245:00AMPR Newswire (US)IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial CancerNASDAQ:IDYAIDEAYA Biosciences Inc
12/09/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 InhibitorNASDAQ:IDYAIDEAYA Biosciences Inc
12/06/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
12/02/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations EventsNASDAQ:IDYAIDEAYA Biosciences Inc
11/29/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
11/18/20245:00AMPR Newswire (US)IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial OfficerNASDAQ:IDYAIDEAYA Biosciences Inc
11/12/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D DayNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/20249:40AMBusiness WireBiocytogen kündigt die Nominierung des Entwicklungskandidaten IDE034 von IDEAYA, einem potenziellen ersten bispezifischen ADC (Antibody Drug Conjugate, Antikörper-Wirkstoff-Konjugat) der Klasse B7H3/PTK7 Topo-I-Nutzlast, sowie die Ausübung der...NASDAQ:IDYAIDEAYA Biosciences Inc
11/11/20249:40AMBusiness WireBiocytogen annonce la nomination par IDEAYA du candidat IDE034, un ADC bispécifique Topo-I-Payload B7H3/PTK7, ainsi que la levée d’une optionNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/20245:00AMBusiness WireBiocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option ExerciseNASDAQ:IDYAIDEAYA Biosciences Inc
11/11/20245:00AMPR Newswire (US)IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with BiocytogenNASDAQ:IDYAIDEAYA Biosciences Inc
11/04/20247:30AMPR Newswire (US)/C O R R E C T I O N -- IDEAYA Biosciences, Inc./NASDAQ:IDYAIDEAYA Biosciences Inc
11/04/20245:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
11/04/20245:00AMPR Newswire (US)IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IDYAIDEAYA Biosciences Inc
11/01/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IDYAIDEAYA Biosciences Inc
10/28/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid TumorsNASDAQ:IDYAIDEAYA Biosciences Inc
10/25/20245:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
10/25/20245:00AMPR Newswire (US)IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024NASDAQ:IDYAIDEAYA Biosciences Inc
10/04/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IDYAIDEAYA Biosciences Inc
10/04/20245:00AMPR Newswire (US)IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR SymposiumNASDAQ:IDYAIDEAYA Biosciences Inc
09/27/20243:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
09/27/20243:21PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IDYAIDEAYA Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:IDYA

Your Recent History

Delayed Upgrade Clock